AI Supercomputer Gefion welcomes new customer Kvantify to Simulate Quantum Computers
Kvantify is leveraging Gefion's GPU-accelerated infrastructure to run and scale its novel simulator optimized for chemistry problems. Kvantify's software includes proprietary algorithms which are essential for accurately modeling molecular systems and reaction pathways relevant to drug design and enzyme engineering.
"Gefion provides exaflop class performance for AI, and its specialized hardware happens to also be perfectly suited for simulated quantum computing," said
The collaboration also highlights Gefion's broader role as an infrastructure backbone for emerging quantum R&D. As quantum technologies continue to evolve, Gefion provides the computational power needed to simulate, test, and refine quantum algorithms, enabling researchers to accelerate breakthroughs in a variety of fields—from materials science to optimization problems.
"Gefion was built to push the boundaries of what's possible with AI infrastructure—and Kvantify is showing how that same AI hardware can deliver impact in quantum computing" said
"Simulating quantum computers is a fundamental step toward unlocking their real-world potential," said
Kvantify's use of Gefion further underscores the AI supercomputer's versatility across domains beyond machine learning, including quantum simulation, molecular modeling, and next-generation HPC workflows. It also reflects a broader trend: the convergence of quantum research and classical infrastructure to solve today's most complex scientific problems.
About Kvantify
Kvantify is a pioneering quantum software company based in
About DCAI
The Danish Centre for AI Innovation (DCAI) owns and operates Gefion,
View original content:https://www.prnewswire.com/news-releases/ai-supercomputer-gefion-welcomes-new-customer-kvantify-to-simulate-quantum-computers-302452749.html
SOURCE Danish Centre for AI Innovation (DCAI)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BlueFaucet Launches Autonomous AI Agent CRM for Solopreneurs and Small Merchants
- Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
- Stuttering Treatment and Research Society (STARS) Releases First Interdisciplinary Consensus Guidelines on Stuttering
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share